

**FORM 51-102F3
MATERIAL CHANGE REPORT**

Item 1. Name and Address of Company

QuikFlo Health Inc. (formerly Viper Gold Ltd.) ("**QuikFlo**" or the "**Company**")
#45 711 Alastair Ross Technology Centre
3553 31 Street NW
Calgary, Alberta
T2L 2K7

Item 2. Date of Material Change

November 23, 2015

Item 3. Report

On November 24, 2015, a press release relating to the material change was issued and disseminated through the services of Marketwired.

Item 4. Summary Of Material Change

The Company announced the closing of the previously announced non-brokered private placement of \$500,000 (the "**Private Placement**") and the completion of the acquisition of all of the issued and outstanding shares of QuikFlo Technologies Inc. (the "**Acquisition**", and together with the Private Placement, the "**Transaction**"). In conjunction with closing of the Transaction, the Company changed its name to "QuikFlo Health Inc."

Item 5. Full Description Of Material Change

On November 24, 2015 QuikFlo announced the completion of the previously announced acquisition of all of the issued and outstanding shares of QuikFlo Technologies Inc. ("**QTI**"). The Acquisition was approved at a special meeting of the shareholders of Viper held on October 30, 2015 (the "**Special Meeting**"). The Acquisition constitutes a "Change of Business" and "Reverse Takeover" for the purposes of the TSX Venture Exchange (the "**Exchange**") and is subject to the final Exchange acceptance. QuikFlo Technologies Inc. holds exclusive worldwide rights to intellectual property that is being developed into an automated diagnostic tool which interprets computerized tomography scans of ischemic stroke patients and provides recommended treatment options to attending physicians. For further information regarding the details of the Acquisition, please refer to the management information circular of QuikFlo dated September 30, 2015 (the "**Circular**"), filed on SEDAR at www.sedar.com under the Company's profile.

Coincident with completion of the Acquisition, the Company completed the Private Placement for of 2,000,000 common shares in the capital of QuikFlo (the "**Common Shares**") at a price of \$0.25 per share for aggregate gross proceeds of \$500,000. The Common Shares issued pursuant to the Private Placement are subject to a hold period expiring March 24, 2016.

At the annual meeting of shareholders of QuikFlo held on April 25, 2014, shareholders passed a special resolution authorizing the Company to change the name of the Company to such name as may be determined by the board of directors. On this basis, immediately prior to closing of the Transaction, the Company changed its name to "QuikFlo Health Inc." and expects the Common Shares to resume trading on the Exchange under the new symbol "QF" on or about November 27, 2015.

Pursuant to the terms of the Transaction, the shareholders of QTI received 3,000 Common Shares in exchange for each Common Share resulting in the issuance of 30,000,000 Common Shares at a deemed

price of \$0.10 per share for aggregate deemed consideration of \$3,000,000. In accordance with the policies of the Exchange, a total of 10,800,000 Common Shares are subject to a value security escrow agreement (the "**Value Escrow Agreement**"), and a total of 21,060,500 Common Shares and 1,200,000 Common Share purchase warrants are subject to a surplus security escrow agreement (the "**Surplus Escrow Agreement**", and together with the Value Escrow Agreement, the "**Escrow Agreements**") entered into in connection with the Transaction. The Escrow Agreements each provide for staged releases over a period of 3 years.

In connection with the Transaction, the Company also granted 4,275,000 incentive stock options ("**Options**") to certain officers, directors and employees, including 3,000,000 Options to Mr. Jindal pursuant to compensation arrangement approved by holders of Common Shares ("**Shareholders**") at the Special Meeting. The Company has determined that in accordance with Exchange policies, despite information that was provided in the Circular, no Options are subject to escrow. Under a new fixed number option plan, also approved by Shareholders at the Special Meeting (the "**New Plan**"), the maximum number of Common Shares issuable under the New Plan and all other security based compensation arrangements of the Company is 7,715,440 Common Shares.

The board of directors of the Company is now composed of Dr. Bjoy K. Menon, Dr. Michael D. Hill, Mr. George Tsafalas and Mr. Rick Skeith. The officers of the Company are Mr. Vinny Jindal (President and Chief Executive Officer), Dr. Ting Yim Lee (Chief Technology Officer) and Mr. Michael Hopkinson (Chief Financial Officer and Corporate Secretary).

As a result of the Transaction, the Company now has 38,577,200 Common Shares outstanding and will have reserved for issuance 7,715,440 Common Shares pursuant to the grant of Options (approximately 4,275,000 of which were granted at closing, as detailed in the Circular) and 3,306,000 Common Shares pursuant to previously issued warrants.

Item 6. Reliance on subsection 7.1(2) of National Instrument 51-102

Not applicable.

Item 7. Omitted Information

No information has been omitted on the basis that it is confidential information.

Item 8. Executive Officer

Vinny Jindal, President and CEO, at 646.526.9628.

Item 9. Date of Report

November 24, 2015.

FORWARD LOOKING INFORMATION

This report contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. More particularly and without limitation, this report contains forward-looking statements and information relating to the listing and reinstatement of trading of the Common Shares on the Exchange, as well as the Company's corporate strategy. The forward-looking statements and information are based on certain key expectations and assumptions made by management of the Company, including, without limitation, the Company's ability to obtain the necessary approvals for the Transaction and the Private Placement, the suitability of the key members of ongoing management and the board of directors, the commercial opportunities available to the Company based on the technology acquired, and the ability of the Company to obtain sufficient funds to commercialize any product. Although management of the Company believes that the expectations and assumptions on which such forward looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information since no assurance can be given that they will prove to be correct.

Forward-looking statements and information are provided for the purpose of providing information about the current expectations and plans of management of the Company relating to the future. Readers are cautioned that reliance on such statements and information may not be appropriate for other purposes, such as making investment decisions. Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. These include, but are not limited to, the Company's ability to identify and complete suitable acquisitions to further the Company's growth, the biomedical and technology sectors in general such as operational risks in development, research and regulatory delays or changes in plans with respect to research projects or capital expenditures; the uncertainty of the market; the uncertainty of estimates and projections relating to costs and expenses; health, safety and environmental risks; marketing and commercialization; loss of markets; competition; incorrect assessment of the value of any technologies acquired and failure to realize the anticipated benefits of such acquisitions; ability to access sufficient capital from internal and external sources; failure to obtain required regulatory and other approvals and changes in legislation, including but not limited to tax laws, and government regulations, and those risks identified in the Circular. Accordingly, readers should not place undue reliance on the forward-looking statements, timelines and information contained in this report. Readers are cautioned that the foregoing list of factors is not exhaustive and additional risks and uncertainties is set forth in the Circular.

The forward-looking statements and information contained in this report are made as of the date hereof and no undertaking is given to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws or the Exchange. The forward-looking statements or information contained in this report are expressly qualified by this cautionary statement.